Table 1.
Baseline description of the evaluated study participants in the individual study centres, data are given as mean ± SD or percentage.
| Munich | Birmingham | Santander | Milan | Heidelberg | Istanbul | |
|---|---|---|---|---|---|---|
| n | 14 | 22 | 12 | 9 | 16 | 9 |
| age (years) | 8.0 ± 2.4 | 9.2 ± 2.4 | 8.9 ± 2.9 | 10.6 ± 3.3 | 8.5 ± 2.1 | 9.3 ± 2.7 |
| male (%) | 71 | 59 | 33 | 67 | 44 | 67 |
| mat. ed. & (%) # | 14 | 36 | 8 | 11 | 40 | 0 |
| weight (kg) | 26.8 ± 8.2 | 35.2 ± 14.8 | 34.3 ± 15.8 | 34.9 ± 14.8 | 32.6 ± 10.8 | 31.6 ± 11.4 |
| VEP15 (ms) * | 119.0 ± 13.5 | 108.5 ± 7.3 | 110.1 ± 5.5 | 110.5 ± 6.5 | 110.6 ± 5.8 | 115.3 ± 4.1 |
| RPM score * | 111.4 ± 20.3 | 101.0 ± 25.1 | 97.1 ± 22.0 | 123.3 ± 19.4 | 97.2 ± 22.0 | 85.6 ± 16.7 |
| LOS T-score * | 55.8 ± 7.5 | 49.3 ± 9.0 | 62.2 ± 10.1 | 58.8 ± 7.9 | 60.8 ± 9.0 | 57.7 ± 8.0 |
| CBCL score | 54.1 ± 12.2 | 48.6 ± 11.9 | 55.2 ± 9.1 | 51.2 ± 10.8 | 53.7 ± 9.9 | 47.1 ± 6.6 |
| Phe (µmol/L) | 230 ± 175 | 347 ± 201 | 303 ± 115 | 338 ± 268 | 323 ± 268 | 364 ± 113 |
| TG (mmol/L) | 1.29 ± 0.63 | 1.14 ± 0.68 | 0.77 ± 0.26 | 0.90 ± 0.30 | 1.17 ± 0.45 | 1.11 ± 0.41 |
| CHOL (mmol/L) | 3.52 ± 0.48 | 3.47 ± 0.78 | 3.63 ± 0.57 | 3.70 ± 0.52 | 3.78 ± 0.55 | 3.40 ± 0.50 |
| DHA * (% wt/wt) | 2.36 ± 0.59 | 2.52 ± 0.77 | 1.46 ± 0.42 | 1.85 ± 0.34 | 2.87 ± 1.01 | 1.36 ± 0.61 |
| ARA (% wt/wt) | 10.17 ± 2.00 | 10.04 ± 2.36 | 9.75 ± 2.39 | 10.30 ± 0.91 | 9.57 ± 1.68 | 11.48 ± 2.53 |
| ALA * (% wt/wt) | 0.35 ± 0.15 | 0.42 ± 0.23 | 0.15 ± 0.06 | 0.16 ± 0.08 | 0.37 ± 0.17 | 0.14 ± 0.10 |
| LA * (% wt/wt) | 22.62 ± 2.54 | 22.15 ± 3.20 | 21.45 ± 3.12 | 19.03 ± 2.21 | 21.37 ± 4.26 | 25.66 ± 3.76 |
# significant differences between study centers according to chi2-test; * significant differences between study centers according to ANOVA; & percentage of mothers who completed school, qualifying for university.